Merck & Co., Inc.
MRKHealthcareNASDAQDrug Manufacturers - General · Last scanned Sep 8, 2026
Scan Results
Daily timeframeMerck & Co., Inc. operates as a healthcare company worldwide. With a market capitalization of $370.89B, it sits in mega-cap territory. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
Market Cap
$370.89B
Beta
0.23
P/E (TTM)
120.26
P/E (Fwd)
15.75
EPS (TTM)
$1.25
EPS (Fwd)
$9.55
ROE
7.0%
ROA
11.9%
Cash
$7.14B
Total Debt
$53.91B
Free CF
$15.17B
52W Change
77.7%
Annual Financials
Cash vs Debt
Where MRK stands vs its 150-day and 200-day moving averages
As of the August 28, 2026 close, MRK finished 23.94% above its 150-day moving average ($120.66) and 29.34% above its 200-day moving average ($115.62). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MRK overbought or oversold?
At the August 28, 2026 close, MRK's RSI(14) was 72.0, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Merck & Co., Inc. carries $53.91B in total debt against $7.14B in cash reserves — debt is roughly 7.5x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $15.17B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 7.0% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 11.9% further supports the picture of efficient asset utilization. Revenue has been relatively flat, moving from $59.28B (2022) to $65.01B (2025).
The relatively low beta of 0.23 suggests MRK is a less volatile holding compared to the broader index. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. At over 50x earnings, MRK carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. No single metric tells the full story. Reviewing MRK's risk profile alongside its fundamentals and technical indicators provides a more complete picture.